GSK plc (GSK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $101.13B
Last updated: Nov 17, 2026 at 11:06 AM ET
GSK plc (GSK) P/E Ratio & Valuation Multiples
GSK trades at 10.5x trailing earnings and 2.3x sales. Its P/S of 2.3x is above its 5-year median of 2.0x. Its forward P/E is 10.0x. The median P/E across 9 similar companies is 19.9x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 5.0% higher over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 10.5x |
| Forward P/E | 10.0x |
| Price to sales | 2.3x |
| Price to book | 4.1x |
| Price to FCF | 11.4x |
| PEG | N/A |
| FCF yield | 8.8% |
Historical Medians
Against its 10-year medians, its P/B is in line.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.3x | 2.0x | N/A |
| P/B | 4.1x | 3.8x | 4.1x |
Valuation History
Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 1.7x in 2024 to 2.3x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $49.04 | 2.3x | 4.5x |
| 2024 | $33.82 | 1.7x | 4.1x |
| 2023 | $37.06 | 2.0x | 3.5x |
| 2022 | $35.14 | 1.9x | 5.6x |
| 2021 | $55.13 | N/A | 3.3x |
| 2020 | $46.00 | N/A | 2.7x |
| 2019 | $58.74 | 2.3x | 5.9x |
| 2018 | $47.76 | N/A | 13.7x |
| 2017 | $44.34 | N/A | 40.4x |
| 2016 | $48.14 | N/A | 421.7x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GSK
What is GSK's forward P/E ratio?
GSK has a forward P/E ratio of 10.0x.
Is GSK stock overvalued?
GNG's valuation label for GSK is Fairly valued. Its P/E of 10.5x compares with a median of 19.9x across 9 similar companies.
What is GSK's price to sales ratio?
GSK has a price to sales ratio of 2.3x.
GSK pages: Overview, Dividends, Financials, Valuation, Competitors, Government Contracts